SANES

11.766

-1.75%↓

BBVA

21.39

-0.7%↓

BNP

102.52

+0.06%↑

CABK

12.23

-2.7%↓

INGA

27.425

-1.38%↓

SANES

11.766

-1.75%↓

BBVA

21.39

-0.7%↓

BNP

102.52

+0.06%↑

CABK

12.23

-2.7%↓

INGA

27.425

-1.38%↓

SANES

11.766

-1.75%↓

BBVA

21.39

-0.7%↓

BNP

102.52

+0.06%↑

CABK

12.23

-2.7%↓

INGA

27.425

-1.38%↓

SANES

11.766

-1.75%↓

BBVA

21.39

-0.7%↓

BNP

102.52

+0.06%↑

CABK

12.23

-2.7%↓

INGA

27.425

-1.38%↓

SANES

11.766

-1.75%↓

BBVA

21.39

-0.7%↓

BNP

102.52

+0.06%↑

CABK

12.23

-2.7%↓

INGA

27.425

-1.38%↓

Search

Ipsen SA.

Nyitva

SzektorPénzügy

162.5 -1.04

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

162

Maximum

165.2

Fő mutatók

By Trading Economics

Bevétel

-225M

110M

Értékesítés

36M

1.9B

P/E

Szektor átlag

29.549

22.989

Osztalékhozam

0.89

Profit margin

5.899

Munkavállalók

5,535

EBITDA

-171M

466M

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

-4.26% downside

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

0.89%

4.69%

Következő eredményjelentés

2026. júl. 30.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

1.6B

13B

Előző nyitás

163.54

Előző zárás

162.5

Hangulat hírek alapján

By Acuity

25%

75%

41 / 439 Rangsor szerint Finance

Ipsen SA. Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Rólunk Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat